NLRP3-IN-51 (Compound 3q) is a potent cholinergic anti-inflammatory pathway ( CAP ) activators. ANLRP3-IN-51 inhibits Monosodium urate (MSU) -induced IL-1β production in THP-1 cells, indicating its potential against gout arthritis. NLRP3-IN-51 inhibits MSU induced phosphorylation of NF-κB p65, without any inhibitory effect against NLRP3 , pro-caspase 1, or the self-cleavage and activation of caspase-1 of the second signaling. Therefore, NLRP3-IN-51 inhibits the initial phase of NLRP3 through CAP activation.